[1]. Pecorino Lauren. Molecular biology of cancer mechanism, targets and therapeuticsy. 2th ed; 2008.
[2]. Cancer Control: a Global Snapshot in 2015 Summary of Results From the 2015 Who Ncd Country Capacity Survey. world Heal. Organ. 2015: 1-6
[3]. Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta (BBA)-General Subj. 2013; 1830(2): 2481-95.
[4]. Tinsley R. Harrison, Braunwald E. Harrison’s Principles of Internal Medicine. 17th ed. New York: The McGraw-Hill Companies, Inc; 2008.
[5]. Pigram W-J, Fuller W, Hamilton LD, Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature. 1972; 235(53): 17-19.
[6]. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000; 256(1): 42-9.
[7]. D. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J. Nucl. Cardiol. 2000; 7(1): 53-62.
[8]. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012; 30(7): 679-92.
[9]. Karewicz A, Bielska D, Loboda A, Gzyl-Malcher B, Bednar J, Jozkowicz A, Dulak J, Nowakowska M. Curcumin-containing liposomes stabilized by thin layers of chitosan derivatives. Colloids Surfaces B Biointerfaces. 2013; 109(1): 307-316.
[10]. Mirahmadi N, Babaei MH, Vali AM, Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int. J. Pharm. 2010; 383(1): 7-13.
[11]. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells, Nanomedicine, Biotechnol. 2016; 44(1): 381-91.
[12]. Cheraghi M, Negahdari B, Daraee H, Etemadi A. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. Biomed Pharmacother. 2017; 86(1): 316-23.
[13]. Mansoori MA, Agrawal S, Jawade S, Khan MI. A review on liposome. 2012; 2(4): 453-64.
[14]. Allen TM, Hansen CB, de Menezes DEL. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev.1995; 16(2): 267-84.
[15]. Wang J, Ma W, Tu P. Synergistically Improved Anti‐tumor Efficacy by Co‐delivery Doxorubicin and Curcumin Polymeric Micelles. Macromol. Biosci. 2015; 15(9): 1252-61.
[16]. Majdizadeh M, Rezaei Zarchi S, Movahedpour AA, Shahi Malmir H, Sasani E, Haghiralsadat BF. A new strategy in improving therapeutic indexes of medicinal herbs: preparation and characterization of nano-liposomes containing Mentha piperita essential oil. J Shaeed Sdoughi Univ Med Sci Yazd. 2018; 25(10): 853-64.
[17]. Haghiralsadat BF, Amouabedini G, Naderinezhad S, Sheikhha MH, Malaei-balasi Z, Akbarzadeh A, et al. An evaluation of the transmembrane ammonium sulfate gradients method in lipid system to improve trapping capacity of amphipathic weak. New Cell Mol Biotechnol J. 2017; 7(28): 49-60
[18]. Rasoulian-broujeni M, Najafi S, Hojati-emami S, Dehghan mohammad mehdi. Preparation and evaluation of nanoparticles containing oxaliplatin for target drug release at the site of breast tumor. Iran J Breast Dis. 2011; 4(3): 33-43.
[19]. Shaikh IM, Tan KB, Chaudhury A, Liu Y, Tan BJB, Chiu GNC. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. J. Control. Release. 2013; 172(3): 852-61.
[20]. Alavi SE, Koohi-moftakhar-esfahani M, Akbarzadeh A. Evaluating the effect of nanoliposomal hydroxyurea urea on the breast cancer cell line. New Cellular & Molecular Biotechnology Journal. 2013; 3: 63-7.
[21]. Fang Y, Wu X, Chen J, Dang S, Jiang D, Chen M, et al. Preparation and Characterization of mPEG Modified Magnetic Long-Circulating Doxorubicin Hydrochloride Liposomes. Adv Mater Res. 2013; 661: 87-90.
[22]. Alavi SE, Koohi-moftakhari-esfahani M, Akbarzadeh A. Cytotoxic activity of pegylated nanoliposomal hydroxyurea in MCF-7 cell line. New Cellular & Molecular Biotechnology Journal. 2014; 4: 33-6.
[23]. Maedeh Koohi moftakhari esfahani, Alavi seyyed ebrahim, Akbaezadeh A. Drug delivery of pegylated nanoliposomal paclitaxel to breast. New Cell Mol Biotechnol J. 2014; 4(14): 47-50.
[24]. Alyane M, Barratt G, Lahouel M. Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. SAUDI Pharm J. 2016; 24(2): 165-75.
[25]. Haghiralsadat BF, Amouabedini G, Sheikhha MH, Mohammadnezhad MJ, Nadernezhad S, Malaei-balasi Z, et al. New Approach for the Synthesis, Entrapment of Hydrophilic Drugs and Evaluation of Physico-Chemical Characteristics of PH-sensitive Nano-Liposome: Improving Therapeutic Efficacy of Doxorubicin in Order to Treatment Bone Tumor and Reducing the Side Effects. J Shaeed Sdoughi Univ Med Sci Yazd. 2016; 24(10): 780-9.
[26]. Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh-doulabi B, Naderinezhad S, Helder MN, et al. New liposomal doxorubicin nanoformulation for osteosarcoma : Drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017; 90(3): 368-79.
[27]. Naderinezhad S, Haghiralsadat BF, Amouabedini G, Naderinezhad A, Esmaeili Z, Akbaezadeh A. Synthesis of biodegradable and self-assembled anionic nano-carrier: Novel approach for improvement of Curcumin- delivery to bone tumors cells & Mathematical modeling of drug-release kinetic. New Cell Mol Biotechnol J. 2017; 7(27): 77-84.
[28]. Shirzad M, Jamehbozorgi S, Aghabozorg H, Akbarzadeh A. Drug Delivery of Pegylated Nanoliposomal Cisplatin in Ovarian Cancer Cell Line A2780CP: in vitro Study. Vol. 7, New Cellular & Molecular Biotechnology Journal. 2017; 7: 77-84.
[29]. Naderinezhad S, Amouabedini G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Adv. 2017; 7(1): 30008-19.
[30]. Haghiralsadat BF, Nadernezhad S, Amoabediny G, Montazeri F, Zandieh-doulabi B. effects of surface charge on cytotoxicity of liposomal Doxorubicin on bone cancer cell line. Daneshvar Med. 2018; 25(133): 19-26.
[31]. Sasani E, Shahi Malmir H, Daneshmand F, Majdizadeh M, Haghiralsadat B F. A new study on synthesize and optimization of PEGylated LipoNiosomal nanocarriers containing curcumin for use in cancer chemotherapy . JSSU. 2018; 26 (6): 528-41